Latest Conference Articles

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.

Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Robert J. Kreitman, MD, discusses the association between minimal residual disease-negativity and complete remission durations in patients with hairy cell leukemia treated with moxetumomab pasudotox.

Justin Taylor, MD, discusses the design of an ongoing phase II clinical trial evaluating the combination of frontline vemurafenib plus obinutuzumab in patients with hairy cell leukemia.

James Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).